We are a biotechnology company dedicated to the research and development of non-invasive systems to support the diagnosis and treatment of digestive diseases based on the intestinal microbiota as a determinant factor
Non-invasive, fast and cost-effective pioneering system for the pre-diagnosis of early stage colorectal cancer without the need for a colonoscopy (Phase I)
Non-invasive, fast and highly sensitive pioneering system for the pre-diagnosis of irritable bowel syndrome, Crohn's disease and ulcerative colitis (Phase I)
Innovative prebiotic therapy for patients with intestinal diseases that promotes the growth of beneficial microorganisms existing in the intestinal flora (Phase I)
We are looking for industrial partners
If you are a MedTech or pharmaceutical company interested in our innovative tests and prebiotics:
Blog
World Inflammatory Bowel Disease Day (ulcerative colitis)
Today is World Inflammatory Bowel Disease (IBD) Day; IBD is a set of chronic ...
Read MoreNews & Events
GoodGut abre una ronda de financiación en Capital Cell para ultimar su test de cáncer colorrectal
INVIERTE GoodGut celebra su quinto aniversario con varios hitos empresariales, médicos y científicos logrados. ...
Read MoreGoodGut signs an agreement with Palex to launch first non-invasive diagnostic tests for IBS and IBD
GoodGut has signed an agreement with Palex Medical to start selling its new non-invasive ...
Read MoreCEO Message
We want to globally introduce a new paradigm in the clinical standars point of care for digestive diseases improving quality life patients
Our values
Know our strategic and scientific partners
Get the latest news of GoodGut
Every quarterly we will send you the newsletter in your email